EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis and Crohn's disease: A real-world cohort study

Yumie Kobayashi, Shuhei Hosomi, Koji Fujimoto, Rieko Nakata, Yu Nishida, Akinari Sawada, Hirotsugu Maruyama, Masaki Ominami, Yuji Nadatani, Koji Otani, Shusei Fukunaga, Yasuhiro Fujiwara

Inflammatory Intestinal Diseases · 10.11.2026

DOI: 10.1159/iid/adeag013 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Inflammatory Intestinal Diseases, online erschienen am 10.11.2026. Verfasst von Yumie Kobayashi und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Real-world data on long-term outcomes and predictors of vedolizumab (VDZ) persistence in ulcerative colitis (UC) and Crohn’s disease (CD) remain limited. This study aimed to evaluate long-term treatment persistence and identify predictors of VDZ persistence in patients with UC and CD.

Methods

This retrospective study included 107 patients (64 UC and 43 CD) treated with VDZ. Treatment persistence was evaluated using the Kaplan–Meier method, and predictors of persistence were analyzed using Cox proportional hazards models.

Results

The median observed treatment duration was 507 days in UC and 266 days in CD. The 1-year persistence rates were 69.4% in UC and 47.5% in CD, while the 2-year persistence rates were 60.2% and 32.5%, respectively. In UC, advanced age was significantly associated with lower VDZ persistence in the Cox model (hazard ratio [HR], 1.29; 95% confidence interval [CI] ,1.06–1.58; p = 0.013). Corticosteroid use at initiation, prior tacrolimus use and prior anti-TNF exposure were not identified as predictors of lower persistence. In CD, perianal disease was significantly associated with lower persistence (log-rank p < 0.01) and remained an independent predictor (HR 2.54, 95% CI 1.20–5.39; p = 0.015).

Conclusions

Predictors of VDZ persistence were identified in both UC and CD. Age was associated with VDZ persistence in UC, while perianal disease was associated with VDZ persistence in CD. These findings may help guide patient selection and treatment strategies for VDZ in clinical practice.

Zitieren

APA

Kobayashi, Y., Hosomi, S., Fujimoto, K., Nakata, R., Nishida, Y., Sawada, A., Maruyama, H., Ominami, M., Nadatani, Y., Otani, K., Fukunaga, S., & Fujiwara, Y. (2026). Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis and Crohn's disease: A real-world cohort study. Inflammatory Intestinal Diseases. https://doi.org/10.1159/iid/adeag013

Vancouver

Kobayashi Y, Hosomi S, Fujimoto K, Nakata R, Nishida Y, Sawada A, et al. Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis and Crohn's disease: A real-world cohort study. Inflammatory Intestinal Diseases. 2026. doi:10.1159/iid/adeag013

BibTeX
@article{Kobayashi2026,
  author = {Kobayashi, Yumie and Hosomi, Shuhei and Fujimoto, Koji and Nakata, Rieko and Nishida, Yu and Sawada, Akinari and Maruyama, Hirotsugu and Ominami, Masaki and Nadatani, Yuji and Otani, Koji and Fukunaga, Shusei and Fujiwara, Yasuhiro},
  title = {Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis and Crohn's disease: A real-world cohort study},
  journal = {Inflammatory Intestinal Diseases},
  year = {2026},
  doi = {10.1159/iid/adeag013}
}
Kostenlos starten →